Evaluation of tau deposition using


Journal

Alzheimer's research & therapy
ISSN: 1758-9193
Titre abrégé: Alzheimers Res Ther
Pays: England
ID NLM: 101511643

Informations de publication

Date de publication:
27 07 2022
Historique:
received: 11 04 2022
accepted: 11 07 2022
entrez: 27 7 2022
pubmed: 28 7 2022
medline: 30 7 2022
Statut: epublish

Résumé

The ability of Subjects with a diagnosis of MCI due to AD or mild AD dementia and a visually amyloid-positive Percentage of visually tau-positive scans increased with amyloid-beta deposition measured in The findings support the hypothesis that Data used in this manuscript belong to a tau PET imaging sub-study of the elenbecestat MissionAD Phase 3 program registered in ClinicalTrials.gov ( NCT02956486 ;  NCT03036280 ).

Sections du résumé

BACKGROUND
The ability of
METHODS
Subjects with a diagnosis of MCI due to AD or mild AD dementia and a visually amyloid-positive
RESULTS
Percentage of visually tau-positive scans increased with amyloid-beta deposition measured in
CONCLUSIONS
The findings support the hypothesis that
TRIAL REGISTRATION
Data used in this manuscript belong to a tau PET imaging sub-study of the elenbecestat MissionAD Phase 3 program registered in ClinicalTrials.gov ( NCT02956486 ;  NCT03036280 ).

Identifiants

pubmed: 35897078
doi: 10.1186/s13195-022-01048-x
pii: 10.1186/s13195-022-01048-x
pmc: PMC9327167
doi:

Substances chimiques

((18)F)PI-2620 0
Amyloid 0
Amyloid beta-Peptides 0
Biomarkers 0
Fluorine Radioisotopes 0
Pyridines 0
tau Proteins 0

Banques de données

ClinicalTrials.gov
['NCT03036280', 'NCT02956486']

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

105

Informations de copyright

© 2022. The Author(s).

Références

JAMA Neurol. 2019 Aug 01;76(8):915-924
pubmed: 31157827
Brain. 2019 Jun 1;142(6):1723-1735
pubmed: 31009046
JAMA Neurol. 2016 Sep 1;73(9):1070-7
pubmed: 27454922
J Nucl Med. 2020 Jun;61(6):920-927
pubmed: 31712324
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2233-2244
pubmed: 32572562
Brain. 2016 May;139(Pt 5):1551-67
pubmed: 26962052
Neuroimage. 2009 May 15;46(1):154-9
pubmed: 19457369
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
N Engl J Med. 2014 Jan 23;370(4):322-33
pubmed: 24450891
Neurology. 1999 Apr 12;52(6):1158-65
pubmed: 10214737
Neurology. 2016 Aug 30;87(9):920-6
pubmed: 27473132
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2178-2189
pubmed: 31264169
J Neuropathol Exp Neurol. 2012 May;71(5):362-81
pubmed: 22487856
J Nucl Med. 2020 Jun;61(6):911-919
pubmed: 31712323
Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2225-2232
pubmed: 33495928
Acta Neuropathol. 1991;82(4):239-59
pubmed: 1759558
Alzheimers Dement. 2015 Jan;11(1):1-15.e1-4
pubmed: 25443857
N Engl J Med. 2021 May 6;384(18):1691-1704
pubmed: 33720637
Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2077-2089
pubmed: 31254035
Alzheimers Res Ther. 2021 Mar 27;13(1):67
pubmed: 33773598
Brain. 2019 Oct 1;142(10):3230-3242
pubmed: 31501889
J Nucl Med. 2017 Aug;58(8):1300-1306
pubmed: 28183994
Neuroimage. 2002 Jan;15(1):273-89
pubmed: 11771995
J Nucl Med. 2018 Dec;59(12):1877-1884
pubmed: 30097505
JAMA Neurol. 2020 Jul 1;77(7):829-839
pubmed: 32338734
Neurology. 2018 Jan 23;90(4):e282-e290
pubmed: 29282337
Lancet Neurol. 2013 Feb;12(2):207-16
pubmed: 23332364
J Alzheimers Dis. 2021;80(3):1091-1104
pubmed: 33682705
J Cereb Blood Flow Metab. 2021 Mar;41(3):579-589
pubmed: 32281514
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
J Nucl Med. 2015 Apr;56(4):567-74
pubmed: 25745095
N Engl J Med. 2014 Jan 23;370(4):311-21
pubmed: 24450890
Neurobiol Aging. 1997 Jul-Aug;18(4):351-7
pubmed: 9330961
Cereb Cortex. 2004 Jan;14(1):11-22
pubmed: 14654453
Brain. 2017 Mar 1;140(3):748-763
pubmed: 28077397
J Nucl Med. 2018 Jul;59(7):1104-1110
pubmed: 29175981
Int J Mol Sci. 2021 Jun 14;22(12):
pubmed: 34198582
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2053-2059
pubmed: 28643043
Alzheimers Res Ther. 2018 Jul 31;10(1):74
pubmed: 30064520
Alzheimers Dement. 2022 Feb;18(2):272-282
pubmed: 34057284

Auteurs

Santiago Bullich (S)

Life Molecular Imaging GmbH, Berlin, Germany. s.bullich@life-mi.com.

Andre Mueller (A)

Life Molecular Imaging GmbH, Berlin, Germany.

Susan De Santi (S)

Eisai Inc, Nutley, NJ, USA.

Norman Koglin (N)

Life Molecular Imaging GmbH, Berlin, Germany.

Stephen Krause (S)

Eisai Inc, Nutley, NJ, USA.

June Kaplow (J)

Eisai Inc, Nutley, NJ, USA.

Michio Kanekiyo (M)

Eisai Inc, Nutley, NJ, USA.

Núria Roé-Vellvé (N)

Life Molecular Imaging GmbH, Berlin, Germany.

Audrey Perrotin (A)

Life Molecular Imaging GmbH, Berlin, Germany.

Aleksandar Jovalekic (A)

Life Molecular Imaging GmbH, Berlin, Germany.

David Scott (D)

Clario, San Mateo, CA, USA.

Michelle Gee (M)

Eisai Limited, Hatfield, UK.

Andrew Stephens (A)

Life Molecular Imaging GmbH, Berlin, Germany.

Michael Irizarry (M)

Eisai Inc, Nutley, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH